Read time: 5 minutes.

This year marks 20 years since researchers made a key discovery that changed the face of lung cancer research and treatment. 

By uncovering EGFR’s role in lung cancer, researchers developed a new class of drugs—targeted therapies—designed to target specific mutations in lung cancer cells while leaving healthy cells unharmed. 

As we’ve welcomed this era of precision medicine, we’ve also benefited from other treatment progress in lung cancer—including the development of effective immunotherapies.  

This is the second blog in our series of updates from the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference, held in Barcelona from September 13-17. This update focuses on small cell lung cancer (SCLC), which is seen in 15% of people diagnosed with lung cancer.  

You can read the other update blogs from these fall science meetings: 

Lung cancer screening and early detection were major topics of discussion at the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference in Barcelona from September 13-17. This fourth and final blog in our series of updates summarizes highlights from these discussions. 

You can read the other update blogs from these fall science meetings: 

Read time: 5 minutes.  

This is Part 3 in our series on how drugs get approved to treat lung cancer.  

Read time: 6 minutes. 

This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development. 

Read time: 3 minutes.

This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks.

Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do.

Read time: 3 minutes.  

One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment.  

Read time: 2 minutes.  

Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials.  

Read time: 8 minutes

Thousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving cancer research at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 through June 4, 2024. 

Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed with advanced-stage lung cancer. Research is ongoing to help us develop effective options to treat these patients medically, but little is known about the effects of the diagnosis on their mental, social, and financial health or their family planning.